Antineutrophil cytoplasmic antibodies (ANCA)–associated vasculitis, or AAV, causes inflammation of the blood vessels and can affect many parts of the body, including multiple organs. Because of this, ...

Initiating mepolizumab within 3 months of EGPA diagnosis is associated with a higher remission rate, earlier glucocorticoid withdrawal, and less damage accrual.

LARGE vessel vasculitis may present as leg pain, and FDG-PET/CT uncovered lower extremity predominant disease in 16 patients ...

Learn the difference between induction and maintenance phases in ANCA-associated vasculitis (AAV) treatment, including what to expect from medications like rituximab (Rituxan).

The REPLENISH trial finds secukinumab doubles the remission rate and significantly lowers steroid use in relapsing ...

Normally, your immune system fights off disease and protects your body from infection. However, when you have an autoimmune disease, your immune system mistakenly attacks healthy cells, tissues and ...

DelveInsight's“ ANCA Vasculitis Pipeline Insight 2025” report provides comprehensive insights about 12+ companies and 12+ pipeline drugs in the ANCA Vasculitis pipeline landscape. It covers the ANCA ...

The predictive variables assessed were age at EGPA diagnosis, baseline eosinophil count, history of chronic sinusitis prior to diagnosis, and glucocorticoid-treated asthma at diagnosis.

Chronic kidney disease is a condition wherein the kidneys are damaged and they aren't able to function as usual. Your kidneys ...

Taiwanese study puts numbers to common but poorly studied phenomenon ...

USANewsGroup.com News Commentary -- The global cell therapy market is projected to surpass $8.2 billion in 2026, driven by a wave of clinical breakthroughs and manufacturing milestones reshaping ...

Company will debut five-year results from GALE study showing meaningful impact of early and continuous treatment with SYFOVRE® (pegcetacoplan ...